Cargando…

Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection

BACKGROUND/AIMS: Hepatitis C Virus (HCV) infection is diagnosed by the presence of antibody to HCV and/or HCV RNA. This study aimed to evaluate the accuracy of anti-HCV titer (S/CO ratio) in predicting HCV viremia in patients with or without hepatitis B virus (HBV) dual infection. METHODS: Anti-HCV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Hung-Yin, Lin, Yi-Hung, Lin, Pei-Ju, Tsai, Pei-Chien, Liu, Shu-Fen, Huang, Ying-Chou, Tsai, Jia-Jiun, Huang, Ching-I, Yeh, Ming-Lun, Liang, Po-Cheng, Lin, Zu-Yau, Dai, Chia-Yen, Huang, Jee-Fu, Chuang, Wan-Long, Huang, Chung-Feng, Yu, Ming-Lung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248640/ https://www.ncbi.nlm.nih.gov/pubmed/34197557 http://dx.doi.org/10.1371/journal.pone.0254028

Ejemplares similares

Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2016)

Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes
por: Huang, Ching-I, et al.
Publicado: (2018)

Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)
por: Huang, Jee-Fu, et al.
Publicado: (2021)

The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan
por: Huang, Ying-Chou, et al.
Publicado: (2021)

Therapy as prevention toward HCV elimination in maintenance hemodialysis: a multi-center, prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2023)

Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR
por: Yeh, Ming-Lun, et al.
Publicado: (2021)

A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic
por: Huang, Ching-I, et al.
Publicado: (2023)

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
por: Chang, Te-Sheng, et al.
Publicado: (2023)

Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Effects of Achieving SVR on Clinical Characteristics and Surgical Outcomes in Patients Who Developed Early-Stage HCV-Related Hepatocellular Carcinoma and Received Curative Resection: Preoperative versus Postoperative SVR
por: Hsu, Po-Yao, et al.
Publicado: (2022)

Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations
por: Sun, Hsin-Yun, et al.
Publicado: (2022)

Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C
por: Tsai, Yi-Shan, et al.
Publicado: (2020)

Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients
por: Tsai, Yi-Shan, et al.
Publicado: (2022)

Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships
por: Hahn, Judith A, et al.
Publicado: (2019)

Optimal Frequency of Hepatitis C Virus (HCV) RNA Testing for Detection of Acute HCV Infection Among At-risk People With Human Immunodeficiency Virus: A Multicenter Study
por: Sun, Hsin-Yun, et al.
Publicado: (2023)

New treatments for HCV: Perspective from Asia
por: Yu, Ming‐Lung, et al.
Publicado: (2015)

Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C: A Nationwide Survey in Taiwan
por: Yu, Ming-Lung, et al.
Publicado: (2015)

Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database
por: Tsai, Pei-Chien, et al.
Publicado: (2017)

Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy
por: Lu, Ming-Ying, et al.
Publicado: (2016)

The relationship of histologic activity to serum ALT, HCV genotype and HCV RNA titers in chronic hepatitis C.
por: Lee, Y. S., et al.
Publicado: (2001)

Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma
por: Lin, Ching-Chih, et al.
Publicado: (2021)

Anti-HCV Signal-to-Cutoff Ratio in Predicting Hepatitis C Viremia
por: Kim, Hyon-Suk
Publicado: (2009)

Serum aminotransferase ratio is independently correlated with hepatosteatosis in patients with HCV: a cross-sectional observational study
por: Lin, Ming-Shyan, et al.
Publicado: (2015)

Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan
por: Tsai, Pei-Chien, et al.
Publicado: (2021)

Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment
por: Huang, Chung-Feng, et al.
Publicado: (2016)

Corrigendum to “Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment” [EBioMedicine 15 (2017) 81–89]
por: Huang, Chung-Feng, et al.
Publicado: (2017)

Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C
por: Huang, Chung-Feng, et al.
Publicado: (2017)

The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan
por: Tsai, Ming-Chao, et al.
Publicado: (2021)

The Usefulness of Anti-HCV Signal to Cut-off Ratio in Predicting Viremia in Anti-HCV in Patients With Hepatitis C Virus Infection
por: Ranjbar Kermani, Fahimeh, et al.
Publicado: (2015)

Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy
por: Lin, Zu-Yau, et al.
Publicado: (2023)

Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease
por: Huang, Jee-Fu, et al.
Publicado: (2023)

Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
por: Liou, Bo-Huang, et al.
Publicado: (2021)

Significance of Anti-HCV Signal-to-Cutoff Ratio in Predicting Hepatitis C Viremia
por: Seo, Yeon Seok, et al.
Publicado: (2009)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
por: Vigón, Lorena, et al.
Publicado: (2019)

Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study
por: Desai, Seema N., et al.
Publicado: (2016)

HCV core antigen plays an important role in the fight against HCV as an alternative to HCV‐RNA detection
por: Wang, Yuhan, et al.
Publicado: (2021)

The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese
por: Lim, Yun-Ping, et al.
Publicado: (2013)

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t6eajjb9g4hp70n0m7h4cuobjp